Latest Content

Melody Tavakoli, OD, said that she has found that workhorse in Johnson & Johnson's Oasys lens family.

A systematic review of 22 studies found Demodex infestation strongly associated with MGD, with MGD prevalence reaching 92% to 99% in symptomatic Demodex blepharitis and significantly worse meibomian gland structure and function in infested patients.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosli (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.

Anna Tichenor, OD, PhD, FAAO, details her poster – one of AOA 2026's Top Five posters – that identified how quickly and how meaningfully patients experience symptom improvement, and which types of symptoms are affected.

A VA case report documents rapid PDR progression to intravitreal anti-VEGF treatment in a patient 6 months after semaglutide initiation, reinforcing AOA monitoring guidance for GLP-1 patients with preexisting DR.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his portion of the "Myopia Matters: Managing Risk, Vision Loss and Control" presentation.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

Mile Brujic, OD, FAAO, details his presentation on how eye care providers can best equip themselves with identifying and mitigating toxicities caused by antibody drug conjugates.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The company said the expanded portfolio will be available in the US and Canada this summer.